

1 **Early Prediction of In-Hospital Death of COVID-19 Patients: A Machine-Learning Model Based**  
2 **on Age, Blood Analyses, and Chest X-Ray Score**

3 **Garrafa E.<sup>1,3§\*</sup>, Vezzoli M.<sup>1\*</sup>, Ravanelli M.<sup>2,4</sup>, Farina D.<sup>2,4</sup>, Borghesi A.<sup>2,4</sup>, Calza S.<sup>1</sup>, Maroldi R.<sup>2,4</sup>**

4 **<sup>1</sup>Department of Molecular and Translational Medicine, University of Brescia**

5 **<sup>2</sup>Department of Medical and Surgical Specialties, Radiological Sciences and Public Health,**  
6 **University of Brescia**

7 **<sup>3</sup>ASST Spedali Civili di Brescia, Department of Laboratory**

8 **<sup>4</sup>ASST Spedali Civili di Brescia, Department of Radiology**

9 **§Corresponding autor**

10 **\*Authors contributed to the manuscript equally**

11 **Keywords: Analytes, COVID-19 Infectious Disease, Random Forests, SMOTE, VIM, PDP**

12 **Abstract**

13 **Background:** To develop and validate an early-warning model to predict in-hospital mortality on  
14 admission of COVID-19 patients at an emergency department (ED).

15 **Methods:** In total, 2782 patients were enrolled between March 2020 and December 2020, including 2106  
16 patients (first wave) and 676 patients (second wave) in the COVID-19 outbreak in Italy. The first-wave  
17 patients were divided into two groups with 1474 patients used to train the model, and 632 to validate it.  
18 The 676 patients in the second wave were used to test the model. Age, 17 blood analytes and Brescia  
19 chest X-ray score were the variables processed using a Random Forests classification algorithm to build  
20 and validate the model. ROC analysis was used to assess the model performances. A web-based death-  
21 risk calculator was implemented and integrated within the Laboratory Information System of the hospital.

22 **Results:** The final score was constructed by age (the most powerful predictor), blood analytes (the  
23 strongest predictors were lactate dehydrogenase, D-dimer, Neutrophil/Lymphocyte ratio, C-reactive  
24 protein, Lymphocyte %, Ferritin std and Monocyte %), and Brescia chest X-ray score. The areas under  
25 the receiver operating characteristic curve obtained for the three groups (training, validating and testing)  
26 were 0.98, 0.83 and 0.78, respectively.

27 **Conclusions:** The model predicts in-hospital mortality on the basis of data that can be obtained in a short  
28 time, directly at the ED on admission. It functions as a web-based calculator, providing a risk score which  
29 is easy to interpret. It can be used in the triage process to support the decision on patient allocation.

30

## 31 **Introduction**

32 Starting from late February 2020, the COVID-19 outbreak struck the north of Italy causing more than  
33 30,000 deaths in Lombardy alone, up to the end of March 2021. At the beginning of the outbreak, the  
34 Spedali Civili di Brescia (SCBH), the university hospital of one of the hardest hit cities in Europe, was  
35 faced with a ‘flash flood’ of severely ill patients seeking admission to the Emergency Department (ED).  
36 For several weeks, their number exceeded the available resources, obliging a continuous organizational  
37 restructuring of the hospital wards (Garrafa et al., 2020b).

38 In those weeks, given the limited evidence of clinically proven predictors (Marengoni et al.,  
39 2021)(Wynants et al., 2020)(Sperrin et al., 2020), prioritizing hospital admission of non-critical patients  
40 was an arduous task. Essentially, the criteria were based on the presence of fever, respiratory symptoms  
41 and the level of blood oxygenation. A significant drawback of this approach was that patients referring  
42 to the ED with very similar clinical findings underwent inconsistent assessments. In this scenario, the  
43 availability of predictors would have been extremely beneficial, not only to triage patients, but also to  
44 monitor hospitalized patients and warn of exacerbation of the outbreaks.

45 Starting from March 2020, all patients referred to EDs underwent a chest X-ray at admission or within a  
46 few hours. With the purpose of grading pulmonary involvement and tracking changes objectively over  
47 time, a chest X-ray severity score was developed (Brescia X-ray score) (Borghesi and Maroldi,  
48 2020)(Maroldi et al., 2020)(Borghesi et al., 2020a)(Borghesi et al., 2020b). The score was able to predict  
49 in-hospital mortality in 302 patients. In addition to the chest X-ray severity score, a dedicated blood  
50 sampling profile was included in the COVID-19 ED work-up (Garrafa et al., 2020a). Among its 17 blood  
51 analytes, the sampling profile encompassed hemachrome, inflammation biomarkers such as C reactive  
52 protein (CRP), lactate dehydrogenase (LDH) and Ferritin, and coagulation markers (Fibrinogen and D-  
53 dimer). Since that time, the medical literature began to encompass an increasing number of studies  
54 advocating the prognostic value of single or grouped blood parameters (Bonetti et al., 2020)(Borghesi et  
55 al., 2020)(Avouac et al., 2021). All of these parameters were present in our COVID-19 sampling profile.

56 This study aims to develop and validate an Early-Warning Model (BS-EWM), predictive of in-hospital  
57 death, based on data that could easily be acquired on admission to the ED: age, simple blood biomarkers  
58 and chest X-ray. The model was constructed based on the analysis of a cohort of 2872 COVID-19 patients  
59 treated in a single reference center over a 10-month period.

60 This paper adheres to the TRIPOD checklist for predictive model development and validation (Collins  
61 et al., 2015).

62 The study was approved by the local ethics committee (NP 4000).

## 63 **Materials and Methods**

64 The dataset contained 2782 COVID-19 symptomatic patients, hospitalized between March and  
65 December 2020 at SCBH after referring to the ED. In all patients, the following variables were retrieved  
66 from the SCBH database: age, sex, length of hospitalization, Brescia X-ray score (Borghesi and Maroldi,  
67 2020), Alive/Dead, and 17 blood analytes acquired at admission (D-dimer, Fibrinogen, lactate  
68 dehydrogenase (LDH), Neutrophils, Lymphocytes, Neutrophil/Lymphocyte ratio (NLR), Lymphocytes  
69 %, Neutrophils %, C-reactive protein (CRP), white blood cell (WBC) count, Basophils, Basophils %,  
70 Eosinophils, Eosinophils %, Monocytes, Monocytes %, standardized Ferritin). Blood tests were acquired  
71 within 24 hours after admission to the hospital.

72 According to the two temporal peaks of incidence of the COVID-19 outbreak in Lombardy, the 2782  
73 patients were divided into two groups: (i) March–April (MA) including 2106 patients admitted during  
74 the first wave; (ii) May–December (MD) including 676 patients in the second wave. Quantitative  
75 variables were described using Mean (SD), Median (IQR) and Range (min–max), while categorical  
76 variables were reported as counts and percentages. The comparisons between groups were performed  
77 using the Wilcoxon rank-sum test for quantitative variables and Fisher’s exact test for qualitative  
78 variables.

79 The relationships between the 17 analytes and the Brescia X-ray score were inspected using the Spearman  
80 correlation coefficient,  $\rho_s$ , and visualizing results using a correlation plot (Dancelli et al., 2013)(Marziano  
81 et al., 2019) (Figure S1).

82 To estimate the BS-EWM, the outcome (Alive/Dead) was modeled using as covariates: (i) Brescia X-ray  
83 score, (ii) 17 analytes, (iii) age. Since most of the covariates analyzed were strongly correlated (multi-  
84 collinearity) (Figure S1) and their relationships with the outcome were non-linear, the BS-EWM was  
85 estimated using Random Forests (Breiman, 2001)(Carpita and Vezzoli, 2012), a non-parametric  
86 machine-learning method (Vezzoli, 2011)(Vezzoli et al., 2017). Moreover, the algorithm is able to

87 manage missing values which are common in clinical studies. The “*on-the-fly-imputation*” algorithm  
88 (Hong and Lynn, 2020) imputes data when it grows the forest handling interactions and non-linearity in  
89 the dataset.

90 Since the prevalence rate of death in the two waves was different (20% in MA vs 12% in MD), a strategy  
91 to generalize results in unbalanced datasets was applied, adopting a rebalancing method able to improve  
92 the detection of patients with a high death-risk.

93 The EWM was developed using the 2106 patients in the first COVID-19 wave (MA 2020) when in-  
94 hospital death prevalence was 20%. Seventy percent of them (1474 patients) were used for training the  
95 model and the remainder (632 patients) for testing it. Patients were randomly assigned to the two  
96 subgroups, and further stratified according to the outcome (Alive/Dead). Consequently, both the training  
97 and testing subgroups included the same rate of deaths (20.09%) as the full sample (2106 patients). With  
98 such a “moderate” incidence of death, the dataset was statistically unbalanced. This limitation could have  
99 implied the development of a model yielding unsatisfactory results in predicting new observations for  
100 the minority class, i.e., patients with death as outcome. An approach to address this limitation is to  
101 oversample the minority class (deceased patients) and, subsequently, create the predictive model (BS-  
102 EWM). The Synthetic Minority Oversampling Technique (SMOTE) (Chawla et al., 2002) was chosen.  
103 The SMOTE function oversamples the minority class by using bootstrapping and  $k$ -nearest neighbor to  
104 synthetically create additional observations belonging to that class (Dead). The procedure is combined  
105 with under-sampling of the majority class (Alive). To determine the optimum number of  $k$ -groups into  
106 which to assign the dataset, a matrix containing the 17 analytes and the Brescia X-ray score was used to  
107 compute the hierarchical cluster analysis (Salvi et al., 2019)(Codonotti et al., 2016). By means of  
108 silhouette analysis,  $k=2$  was determined as the optimal number of clusters into which to assign the dataset.  
109 Hence, a synthetic rebalanced dataset was obtained with an equal number of Living and Deceased  
110 patients (888+888). The rebalancing procedure enabled a risk score to be devised ranging from 0 to 1  
111 with a threshold of 0.5 to separate non-severely affected from severely affected patients. Subsequently,  
112 the model was tested on the subgroup of 632 patients in the first wave excluding the training set. A further  
113 validation of the EWM was conducted on the 676 COVID-19 patients in the second wave (MD 2020).

114 The Relative Variable Importance Measure (rel VIM)(Carpita and Vezzoli, 2012)(Doglietto et al.,  
115 2020b) and the Partial Dependence Plots (PDP) (Friedman, 2001)(Doglietto et al., 2020a) were extracted  
116 from the model for a better understanding of the relationship between outcome and covariates.

117 The predictions extracted from the Random Forests classification were interpreted as in-hospital death  
118 probability conditional on the combination of the values of analytes, Brescia X-ray score and age in  
119 COVID-19 patients at admission to the ED.

120 The BS-EWM performance was evaluated by Area Under the Curve (AUC) of a Receiver Operating  
121 Characteristic (ROC) curve. The robustness of the model was compared to other models by running  
122 Gradient Boosting Machine (GBM, a machine-learning approach and competitor to Random Forests),  
123 and Logistic Regression, and computing the same metrics.

124 The BS-EWM score is available for use online (<https://bdbiomed.shinyapps.io/covid19score>). In the  
125 SCBH it is integrated within LIS (Laboratory Information System) returning the death-risk score directly  
126 from the medical report.

## 127 **Results**

### 128 **Description of the sample**

129 The entire sample analyzed in this paper contained 2782 COVID-19 patients (1010 female (36.3%) and  
130 1772 male (63.7%)), admitted to the ED and hospitalized at SCBH from March to December 2020.  
131 During these 10 months, the pandemic had two temporal waves: March–April (2106 patients, 75.70% of  
132 the entire sample) and May–December (676 patients, 24.30% of the entire sample) (Table S1). The model  
133 was trained on a subsample extracted from the first wave (70%) and tested (*i*) on data not used to calibrate  
134 the model (remaining 30% from the first wave) and (*ii*) on data from the second wave.

135 The first-wave subsample contained 2106 COVID-19 patients hospitalized in March–April 2020 at  
136 SCBH: 744 females (35.3%), and 1362 males (64.7%) (Table 1). During that period, 423 patients died  
137 (20.09% of the total): 131 females (31%) and 292 males (69%). Their mean age $\pm$ SD was 66.89 $\pm$ 14.19:  
138 67.93 $\pm$ 15.40 for females and 66.32 $\pm$ 13.45 for males (p-value=0.001). The mean age of deceased patients  
139 was 76.21 $\pm$ 9.12, while for living patients, it was 64.55 $\pm$ 14.27 (p-value < 0.001). Mean hospital stay was  
140 13.58 $\pm$ 11.58 days (from a minimum of 0 to a maximum of 140 days): 11.33 $\pm$ 10.98 days for patients who  
141 died, 14.15 $\pm$ 11.66 days for surviving patients (p-value < 0.001).

142 The second-wave subsample contained 676 COVID-19 patients hospitalized in May–December 2020 at  
143 SCBH: 266 females (39.3%), 410 males (60.7%) (Table 1). During the 8 months of the second wave, 82  
144 patients died (12.13%): 26 females (31.7%) and 56 males (68.3%). The mean age of deceased patients  
145 was  $76.72 \pm 10.79$  versus  $65.30 \pm 15.20$  for surviving patients ( $p$ -value  $< 0.001$ ). The mean hospital stay  
146 was  $15.35 \pm 11.58$  days (from a minimum of 0 to a maximum 79 days):  $17.77 \pm 10.75$  days for patients who  
147 died,  $14.95 \pm 11.67$  days for surviving patients ( $p$ -value=0.008).

148 The descriptive statistics for all variables in the dataset are presented in Table S2 and were computed and  
149 stratified by the two waves (MA vs MD) and by outcome (Alive vs Dead). The two subsets were similar  
150 for most variables.

151 The correlations between the 17 analytes and the Brescia X-ray score were investigated using Spearman  
152 correlation coefficients and visualized using a correlation plot (Figure S1). The Brescia X-ray score was  
153 positively correlated with Neutrophil to Lymphocyte ratio, CRP, LDH, standardized Ferritin, and D-  
154 Dimer, and was negatively correlated with Lymphocyte %, Monocyte %, and Basophil %.

## 155 **BS-EWM**

156 A machine-learning model (BS-EWM) was developed by inputting a dataset of 2782 COVID-19 patients  
157 admitted to the ED and hospitalized at SCBH from March to December 2020. The majority of patients  
158 (2106/2782, 75.70%) belonged to the first wave (MA), the remaining fraction (676/2782, 24.30%) to the  
159 second wave (MD). As outcome, the machine-learning model had the condition Dead/Alive, and, as  
160 covariates: age, Brescia X-ray score and 17 blood sample analytes.

161 Figure 1 reports the flow chart that describes how data were divided for training, validation and testing  
162 the BS-EWM.

163 The SMOTE procedure, rebalancing the Dead/Alive ratio (50% vs. 50%) from the original 20.09%,  
164 improved accuracy, specificity, and sensitivity of the Random Forest applied on it (see Table S3 which  
165 compares performance metrics with/without the SMOTE method).

166 The rel VIM and PDP were extracted from the Random Forests (Figure 2, panel A and B respectively).  
167 In panel A1, the rel VIM of BS-EWM based on age, Brescia X-ray score and 17 blood analytes are  
168 reported on a bar plot. Since age was strongly associated with the risk of death, it masked the role of the



169 other covariates. For completeness, the relevance of the 17 analytes and Brescia X-ray score was  
170 estimated in an additional EWM, in which the covariate ‘age’ was excluded. In the resulting bar plot  
171 (Figure 2, panel A2), 9/17 analytes and the Brescia X-ray score were noted as being important in  
172 predicting the risk of death (rel VIM>60). The effects of changes in covariate values on the risk of death-  
173 threshold of the EWM were reported by means of a PDP (a 2D plot in the x–y plane) (Figure 2, panel  
174 B). Only Fibrinogen was excluded from this graphical representation since in Table 1, it was not  
175 significantly different in the two subpopulations Deceased/Alive. Most PDPs showed nonmonotonic  
176 increasing relationships between the  $x$ -variable and the EWM, resulting in a plateau corresponding to  
177 high values of  $x$ .

178 When compared to other models such as GBM and Logistic Regression, the Random Forest showed  
179 better performance in terms of AUC, sensitivity, and specificity. The in-sample sensitivity (0.93) yielded  
180 by the model was the highest, and it maintained an important 0.82 in validating the out-of-sample  
181 sensitivity, and this decreased to 0.73 when testing the MD subgroup (see Table 2 which contains details  
182 on all the metrics extracted from the ROC analysis). ROC curves are visualized in Figure 3 where, for  
183 each model (Random Forest, GBM and Logistic Regression), the performances in Training, Validating  
184 and Testing are compared in a unique graph.

## 185 **Discussion**

186 The dataset for the development, validation and testing of the BS-EWM originated entirely from an  
187 Italian region, potentially limiting the generalizability of the risk score in other areas of the world.  
188 Additional validation studies from different geographic areas are welcomed. Furthermore, though the  
189 BS-EWM has been validated using blood sample values obtained by instruments that satisfy internal and  
190 external quality control, different equipment could lead to divergent results (Martens et al., 2021)(Lippi  
191 et al., 2020). Therefore, it would be appropriate to harmonize the results. Another limit could have been  
192 the presence of missing values, though the BS-EWM has also performed adequately in this condition  
193 since it used a multiple imputation technique to overcome the problem. Finally, it is important to point  
194 out that the BS-EWM risk score should not be used for asymptomatic COVID-19 patients or for the  
195 pediatric population.



196 Though the BS-EWM has been developed on a cohort of 2106 patients belonging to the COVID-19 first  
197 wave, the model also demonstrated a sensitivity greater than 70% in the early prediction of high risk in  
198 patients in the second wave, when in-hospital mortality was 40% lower.

199 Several predictive models have recently been applied to COVID-19 cohorts with variable results, some  
200 of them previously developed to predict mortality for community-acquired pneumonia, such as the  
201 Pneumonia Severity Index, CURB-65, qSOFA, and MuLBSTA(Yavuz et al., 2021)(Lazar Neto et al.,  
202 2021)(Artero et al., 2021), NEWS2 criteria (Myrstad et al., 2020)(Gidari et al., 2020), and SCAP score  
203 (Anurag and Preetam, n.d.). Novel early-warning scores have been specifically built on COVID-19  
204 patient series using different techniques such as parametric and non-parametric tests (Linssen et al., 2020)  
205 or artificial intelligence techniques such as the COVID-GRAM score (Liang et al., 2020).

206 While these models are mostly based on age and a set of vital (clinical) parameters, in addition to age,  
207 the BS-EWM depends on blood parameters. It is conceivable that blood analytes capture a snapshot at  
208 hospital admission signaling a specific bodily reaction to viral infection in terms of hyperinflammation,  
209 immune response and thrombophilia. On the other hand, the other models are more influenced by the  
210 general status of the patient, which may be determined by concomitant and pre-existing diseases.

211 According to the International Federation of Clinical Chemistry (Bohn et al., 2020), no single  
212 biochemical or hematological marker is sufficiently sensitive or specific to predict the outcome of SARS-  
213 CoV-2 infection. Notably, the IFCC recommends that the interpretation of laboratory abnormalities  
214 should be based on groups of analytes (Bohn et al., 2020). In the BS-EWM, three analytes reached a  
215 significant value in predicting death: LDH, D-dimer and NLR. LDH is a non-specific indicator of tissue  
216 damage (Bohn et al., 2020)(Liang et al., 2020) that emerges as one of the most consistently elevated  
217 markers in patients at higher risk of developing adverse outcomes, probably because COVID-19 infection  
218 is characterized by systemic tissue damage. Another key feature of SARS-CoV-2 is the coagulopathy:  
219 high levels of D-dimers have been reported to correlate with unfavorable disease progression in several  
220 cohorts of patients. The coagulopathy linked to COVID-19 infection is likely to involve a complex  
221 interplay between pro-thrombotic and inflammatory factors, thus the combined analysis of both  
222 inflammatory and thrombophilic markers could play an important role in the early identification of  
223 patients at higher risk of unfavorable progression (Bohn et al., 2020)(Lazzaroni et al., 2021). Finally,  
224 lymphopenia has become a hallmark of SARS-CoV-2. It has been demonstrated in almost all  
225 symptomatic patients, though in varying degrees. Disease severity has been correlated with the level of

226 lymphocyte count reduction. A direct infection of lymphocytes, which express the coronavirus receptor  
227 ACE-2, is among the mechanisms proposed. A poor prognosis is also associated with an elevated  
228 neutrophil count combined with lymphopenia, resulting in a high NLR. The increase in granulocytes is  
229 the result of the cytokine storm induced by the virus and is responsible for tissue damage (Bonetti et al.,  
230 2020)(Bohn et al., 2020).

231 A further remark concerning the blood analytes is that, in the BS-EWM, the thresholds of the single  
232 analytes exceeding the 0.5 death-risk closely overlap with the values recently proposed by other authors  
233 (Webb et al., 2020)(Caricchio et al., 2021) (Figure 2, panel B).

234 The present study is not unique in encompassing radiological findings combined with blood analysis.  
235 The study by Schalekamp et al. (Schalekamp et al., 2020) integrated blood analysis parameters and  
236 radiological information derived by grading chest X-rays (0–8 scale points). Unlike the cited study, with  
237 the BS-EWM in this study, the radiological score did not reach a high relevance (rel VIM) in predicting  
238 high risk. This difference can be explained by the different approaches used to build the model (Logistic  
239 regression vs Random Forests) and by the high degree of correlation of the X-ray score with multiple  
240 blood analytes: “collinearity” thus could have “stolen” importance from the information provided by  
241 imaging. Nevertheless, at admission, the chest X-ray score of patients who subsequently died was  
242 significantly higher than for patients who survived. Furthermore, the chest X-ray score may provide  
243 additional stability to the model, playing an important role in the case of missing data in the blood sample  
244 counterpart.

245 An important and pragmatic aspect offered by the BS-EWM is that the biomarkers employed may be  
246 obtained by the emergency laboratory in less than an hour (Garrafa et al., 2020a) and, differently from  
247 other biomarkers (Kyriazopoulou et al., 2021, p. 19), they are non-expensive and frequently used also in  
248 developing countries. It is important to note that the same methodology could be applied to other  
249 infections and be practical to triage people.

250 Most laboratories, including the small or peripheral ones, may provide results in a short time. At the  
251 Spedali Civili of Brescia, the BS-EWM is integrated within the Laboratory Information System. It works  
252 as a web-based calculator and is easy to interpret. It provides a risk threshold of 0.5, above which patients  
253 are graded as having a potentially high death-risk, thus supporting closer clinical observation or

254 admission to a high-intensive care ward. In patients yielding a low risk (score 0 to 0.49), the decision by  
255 clinicians to allocate them to a low-intensive care ward or to monitoring is further sustained.

256 Finally, the need to regularly update models and closely monitor their performances over time and  
257 geographically should be underlined, given the rapidly changing nature of the disease and its  
258 management.

## 259 References

- 260 Anurag A, Preetam M. n.d. Validation of PSI/PORT, CURB-65 and SCAP scoring system in COVID-  
261 19 pneumonia for prediction of disease severity and 14-day mortality. *Clin Respir J* n/a.  
262 doi:<https://doi.org/10.1111/crj.13326>
- 263 Artero A, Madrazo M, Fernández-Garcés M, Muiño Miguez A, González García A, Crestelo Vieitez A,  
264 García Guijarro E, Fonseca Aizpuru EM, García Gómez M, Areses Manrique M, Martínez  
265 Cilleros C, Fidalgo Moreno MDP, Loureiro Amigo J, Gil Sánchez R, Rabadán Pejenaute E,  
266 Abella Vázquez L, Cañizares Navarro R, Solís Marquínez MN, Carrasco Sánchez FJ, González  
267 Moraleja J, Montero Rivas L, Escobar Sevilla J, Martín Escalante MD, Gómez-Huelgas R,  
268 Ramos-Rincón JM, SEMI-COVID-19 Network. 2021. Severity Scores in COVID-19 Pneumonia:  
269 a Multicenter, Retrospective, Cohort Study. *J Gen Intern Med*. doi:10.1007/s11606-021-06626-  
270 7
- 271 Avouac J, Drumez E, Hachulla E, Seror R, Geogin-Lavialle S, Mahou SE, Pertuiset E, Pham T, Marotte  
272 H, Servettaz A, Domont F, Chazerain P, Devaux M, Claudepierre P, Langlois V, Mekinian A,  
273 Maria ATJ, Banneville B, Fautrel B, Pouchot J, Thomas T, Flipo R-M, Richez C. 2021. COVID-  
274 19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with  
275 rituximab: a cohort study. *Lancet Rheumatol* **0**. doi:10.1016/S2665-9913(21)00059-X
- 276 Bohn MK, Lippi G, Horvath A, Sethi S, Koch D, Ferrari M, Wang C-B, Mancini N, Steele S, Adeli K.  
277 2020. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC  
278 taskforce evaluation of the latest evidence. *Clin Chem Lab Med* **58**:1037–1052.  
279 doi:10.1515/cclm-2020-0722
- 280 Bonetti G, Manelli F, Patroni A, Bettinardi A, Borrelli G, Fiordalisi G, Marino A, Menolfi A, Saggini S,  
281 Volpi R, Anesi A, Lippi G. 2020. Laboratory predictors of death from coronavirus disease 2019  
282 (COVID-19) in the area of Valcamonica, Italy. *Clin Chem Lab Med CCLM* **58**:1100–1105.  
283 doi:10.1515/cclm-2020-0459
- 284 Borghesi A, Maroldi R. 2020. COVID-19 outbreak in Italy: experimental chest X-ray scoring system for  
285 quantifying and monitoring disease progression. *Radiol Med (Torino)* **125**:509–513.  
286 doi:10.1007/s11547-020-01200-3
- 287 Borghesi A, Zigliani A, Golemi S, Carapella N, Maculotti P, Farina D, Maroldi R. 2020a. Chest X-ray  
288 severity index as a predictor of in-hospital mortality in coronavirus disease 2019: A study of 302  
289 patients from Italy. *Int J Infect Dis* **96**:291–293. doi:10.1016/j.ijid.2020.05.021
- 290 Borghesi A, Zigliani A, Masciullo R, Golemi S, Maculotti P, Farina D, Maroldi R. 2020b. Radiographic  
291 severity index in COVID-19 pneumonia: relationship to age and sex in 783 Italian patients. *Radiol*  
292 *Med (Torino)* 1–4. doi:10.1007/s11547-020-01202-1
- 293 Borghi MO, Beltagy A, Garrafa E, Curreli D, Cecchini G, Bodio C, Grossi C, Blengino S, Tincani A,  
294 Franceschini F, Andreoli L, Lazzaroni MG, Piantoni S, Masneri S, Crisafulli F, Brugnoli D,  
295 Muiesan ML, Salvetti M, Parati G, Torresani E, Mahler M, Heilbron F, Pregnotato F, Pengo M,

- 296 Tedesco F, Pozzi N, Meroni PL. 2020. Anti-Phospholipid Antibodies in COVID-19 Are Different  
297 From Those Detectable in the Anti-Phospholipid Syndrome. *Front Immunol* **11**.  
298 doi:10.3389/fimmu.2020.584241
- 299 Breiman L. 2001. Random Forests. *Mach Learn* **45**:5–32. doi:10.1023/A:1010933404324
- 300 Caricchio R, Gallucci M, Dass C, Zhang X, Gallucci S, Fleece D, Bromberg M, Criner GJ. 2021.  
301 Preliminary predictive criteria for COVID-19 cytokine storm. *Ann Rheum Dis* **80**:88–95.  
302 doi:10.1136/annrheumdis-2020-218323
- 303 Carpita M, Vezzoli M. 2012. Statistical evidence of the subjective work quality: the fairness drivers of  
304 the job satisfaction. *Electron J Appl Stat Anal* **5**:89–107. doi:10.1285/i20705948v5n1p89
- 305 Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. 2002. SMOTE: Synthetic Minority Over-sampling  
306 Technique. *J Artif Intell Res* **16**:321–357. doi:10.1613/jair.953
- 307 Codenotti S, Vezzoli M, Poliani PL, Cominelli M, Bono F, Kabbout H, Faggi F, Chiarelli N, Colombi  
308 M, Zanella I, Biasiotto G, Montanelli A, Caimi L, Monti E, Fanzani A. 2016. Caveolin-1,  
309 Caveolin-2 and Cavin-1 are strong predictors of adipogenic differentiation in human tumors and  
310 cell lines of liposarcoma. *Eur J Cell Biol* **95**:252–264. doi:10.1016/j.ejcb.2016.04.005
- 311 Collins GS, Reitsma JB, Altman DG, Moons KGM. 2015. Transparent reporting of a multivariable  
312 prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMJ*  
313 **350**:g7594. doi:10.1136/bmj.g7594
- 314 Dancelli L, Manisera M, Vezzoli M. 2013. On Two Classes of Weighted Rank Correlation Measures  
315 Deriving from the Spearman's  $\rho$  In: Giudici P, Ingrassia S, Vichi M, editors. *Statistical Models  
316 for Data Analysis, Studies in Classification, Data Analysis, and Knowledge Organization*.  
317 Heidelberg: Springer International Publishing. pp. 107–114. doi:10.1007/978-3-319-00032-9\_13
- 318 Doglietto F, Vezzoli M, Biroli A, Saraceno G, Zanin L, Pertichetti M, Calza S, Agosti E, Aliaga Arias  
319 JM, Assietti R, Bellocchi S, Bernucci C, Bistazzoni S, Bongetta D, Fanti A, Fioravanti A, Fiorindi  
320 A, Franzin A, Locatelli D, Pugliese R, Roca E, Sicuri GM, Stefani R, Venturini M, Vivaldi O,  
321 Zattra C, Zoia C, Fontanella MM. 2020a. Anxiety in neurosurgical patients undergoing nonurgent  
322 surgery during the COVID-19 pandemic. *Neurosurg Focus* **49**:E19.  
323 doi:10.3171/2020.9.FOCUS20681
- 324 Doglietto F, Vezzoli M, Gheza F, Lussardi GL, Domenicucci M, Vecchiarelli L, Zanin L, Saraceno G,  
325 Signorini L, Panciani PP, Castelli F, Maroldi R, Rasulo FA, Benvenuti MR, Portolani N,  
326 Bonardelli S, Milano G, Casiraghi A, Calza S, Fontanella MM. 2020b. Factors Associated With  
327 Surgical Mortality and Complications Among Patients With and Without Coronavirus Disease  
328 2019 (COVID-19) in Italy. *JAMA Surg*. doi:10.1001/jamasurg.2020.2713
- 329 Friedman JH. 2001. Greedy function approximation: A gradient boosting machine. *Ann Stat* **29**:1189–  
330 1232. doi:10.1214/aos/1013203451

- 331 Garrafa E, Brugnoli D, Barbaro M, Andreoli L, Focà E, Salvetti M, Castelli F, Franceschini F, Piva S,  
332 Muiesan ML, Latronico N, Levaggi R. 2020a. Laboratory considerations amidst the coronavirus  
333 disease 2019 outbreak: the Spedali Civili in Brescia experience. *Bioanalysis* **12**:1223–1230.  
334 doi:10.4155/bio-2020-0109
- 335 Garrafa E, Levaggi R, Miniaci R, Paolillo C. 2020b. When fear backfires: Emergency department  
336 accesses during the Covid-19 pandemic. *Health Policy Amst Neth* **124**:1333–1339.  
337 doi:10.1016/j.healthpol.2020.10.006
- 338 Gidari A, Socio GVD, Sabbatini S, Francisci D. 2020. Predictive value of National Early Warning Score  
339 2 (NEWS2) for intensive care unit admission in patients with SARS-CoV-2 infection. *Infect Dis*  
340 **52**:698–704. doi:10.1080/23744235.2020.1784457
- 341 Hong S, Lynn HS. 2020. Accuracy of random-forest-based imputation of missing data in the presence of  
342 non-normality, non-linearity, and interaction. *BMC Med Res Methodol* **20**:199.  
343 doi:10.1186/s12874-020-01080-1
- 344 Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G, Gatselis N, Karakike E,  
345 Saridaki M, Loli G, Stefos A, Prasianaki D, Georgiadou S, Tsachouridou O, Petrakis V, Tsiakos  
346 K, Kosmidou M, Lygoura V, Dareioti M, Milionis H, Papanikolaou IC, Akinosoglou K, Myrodia  
347 D-M, Gravvani A, Stamou A, Gkavogianni T, Katrini K, Marantos T, Trontzas IP, Syrigos K,  
348 Chatzis L, Chatzis S, Vechlidis N, Avgoustou C, Chalvatzis S, Kyprianou M, van der Meer JW,  
349 Eugen-Olsen J, Netea MG, Giamarellos-Bourboulis EJ. 2021. An open label trial of anakinra to  
350 prevent respiratory failure in COVID-19. *eLife* **10**. doi:10.7554/eLife.66125
- 351 Lazar Neto F, Marino LO, Torres A, Cilloniz C, Meirelles Marchini JF, Garcia de Alencar JC, Palomeque  
352 A, Albacar N, Brandão Neto RA, Souza HP, Ranzani OT, Bortolotto AL, Müller Veiga AD,  
353 Bellintani AP, Fantinatti BL, Nicolao BR, Caldeira BT, Umehara Juck CE, Bueno CG, Takamune  
354 DJ, Guidotte DV, D'Souza EA, Oliveira Silva EC, Brito Miyaguchi ET, Gomes da Silva EM,  
355 Santos Moreira EL, Fonseca e Silva FM, de Paula Maroni Escudeiro G, Travessini G, Costa GB,  
356 Tibucheski dos Santos H, Omori IH, Baptista JM, Afonso Nascimento JP, de Góes Campos L,  
357 Lima LT, Boscolo L, Aduara Pandolfi MC, de Oliveira Silva M, Sanches MP, Saad Menezes  
358 MC, Gonçalves Cimatti De Calasans MM, Lima de Faria MF, Bezerra Martins NA, Albuquerque  
359 de Moura P, Araújo Simões PA, Luna RB, Nishiaka RK, Miléo RC, de Souza Abreu R, Toccoli  
360 RW, Monsalvarga TC, Brito Medeiros VM, Filippo Fernandes YS, Simões AL, Tavares AA,  
361 Carvalho de Alves Pereira C, Ribeiro DR, Dias de Francesco D, Emerenciano DL, Pires de  
362 Campos EM, Moreira FL, Bortoleto FM, Martinez G, Wiebelling da Silva G, Martins GB, Leite  
363 Fortes JC, Dias Barreto LG, Silva de Rosa ML, Ursoline do Nascimento M, Pisciolaro RF, Xavier  
364 RA, Barbosa de Souza SF, Lisboa Netto TA, Ribeiro S, Faria C, Rahhal H, Padrão E, Valente F,  
365 Padovan Chio YH, Gomez Gomez LM. 2021. Community-acquired pneumonia severity  
366 assessment tools in patients hospitalized with COVID-19: a validation and clinical applicability  
367 study. *Clin Microbiol Infect*. doi:10.1016/j.cmi.2021.03.002
- 368 Lazzaroni MG, Piantoni S, Masneri S, Garrafa E, Martini G, Tincani A, Andreoli L, Franceschini F.  
369 2021. Coagulation dysfunction in COVID-19: The interplay between inflammation, viral  
370 infection and the coagulation system. *Blood Rev* **46**:100745. doi:10.1016/j.blre.2020.100745



- 371 Liang W, Liang H, Ou L, Chen B, Chen A, Li C, Li Y, Guan W, Sang L, Lu J, Xu Y, Chen G, Guo H,  
372 Guo J, Chen Z, Zhao Y, Li S, Zhang N, Zhong N, He J, for the China Medical Treatment Expert  
373 Group for COVID-19. 2020. Development and Validation of a Clinical Risk Score to Predict the  
374 Occurrence of Critical Illness in Hospitalized Patients With COVID-19. *JAMA Intern Med*  
375 **180**:1081. doi:10.1001/jamainternmed.2020.2033
- 376 Linssen J, Ermens A, Berrevoets M, Seghezzi M, Previtali G, van der Sar-van der Brugge S, Russcher  
377 H, Verbon A, Gillis J, Riedl J, de Jongh E, Saker J, Münster M, Munnix IC, Dofferhof A,  
378 Scharnhorst V, Ammerlaan H, Deiteren K, Bakker SJ, Van Pelt LJ, Kluiters-de Hingh Y, Leers  
379 MP, van der Ven AJ. 2020. A novel haemocytometric COVID-19 prognostic score developed  
380 and validated in an observational multicentre European hospital-based study. *eLife* **9**:e63195.  
381 doi:10.7554/eLife.63195
- 382 Lippi G, Henry BM, Hoehn J, Benoit S, Benoit J. 2020. Validation of the Corona-Score for rapid  
383 identification of SARS-CoV-2 infections in patients seeking emergency department care in the  
384 United States. *Clin Chem Lab Med CCLM* **58**:e311–e313. doi:10.1515/cclm-2020-1121
- 385 Marengoni A, Zucchelli A, Vetrano DL, Armellini A, Botteri E, Nicosia F, Romanelli G, Beindorf EA,  
386 Giansiracusa P, Garrafa E, Ferrucci L, Fratiglioni L, Bernabei R, Onder G. 2021. Beyond  
387 Chronological Age: Frailty and Multimorbidity Predict In-Hospital Mortality in Patients With  
388 Coronavirus Disease 2019. *J Gerontol Ser A* **76**:e38–e45. doi:10.1093/gerona/glaa291
- 389 Maroldi R, Rondi P, Agazzi GM, Ravanelli M, Borghesi A, Farina D. 2020. Which role for chest x-ray  
390 score in predicting the outcome in COVID-19 pneumonia? *Eur Radiol*. doi:10.1007/s00330-020-  
391 07504-2
- 392 Martens RJH, Adrichem AJ van, Mattheij NJA, Brouwer CG, Twist DJL van, Broerse JJCR, Magro-  
393 Checa C, Dongen CMP van, Mostard RLM, Ramiro S, Landewé RBM, Leers MPG. 2021.  
394 Hemocytometric characteristics of COVID-19 patients with and without cytokine storm  
395 syndrome on the sysmex XN-10 hematology analyzer. *Clin Chem Lab Med CCLM* **59**:783–793.  
396 doi:10.1515/cclm-2020-1529
- 397 Marziano M, Tonello S, Cantù E, Abate G, Vezzoli M, Rungratanawanich W, Serpelloni M, Lopomo  
398 NF, Memo M, Sardini E, Uberti D. 2019. Monitoring Caco-2 to enterocyte-like cells  
399 differentiation by means of electric impedance analysis on printed sensors. *Biochim Biophys Acta*  
400 *Gen Subj* **1863**:893–902. doi:10.1016/j.bbagen.2019.02.008
- 401 Myrstad M, Ihle-Hansen H, Tveita AA, Andersen EL, Nygård S, Tveit A, Berge T. 2020. National Early  
402 Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from  
403 Covid-19 – a prospective cohort study. *Scand J Trauma Resusc Emerg Med* **28**:66.  
404 doi:10.1186/s13049-020-00764-3
- 405 Salvi A, Vezzoli M, Busatto S, Paolini L, Faranda T, Abeni E, Caracausi M, Antonaros F, Piovesan A,  
406 Locatelli C, Cocchi G, Alvisi G, De Petro G, Ricotta D, Bergese P, Radeghieri A. 2019. Erratum:  
407 Analysis of a nanoparticle-enriched fraction of plasma reveals miRNA candidates for down  
408 syndrome pathogenesis(*Int J Mol Med* (2019) 43(2303–2318) DOI: 10.3892/ijmm.2019.4158).  
409 *Int J Mol Med* **44**:768. doi:10.3892/ijmm.2019.4222



- 410 Schalekamp S, Huisman M, van Dijk RA, Boomsma MF, Freire Jorge PJ, de Boer WS,  
411 Herder GJM, Bonarius M, Groot OA, Jong E, Schreuder A, Schaefer-Prokop CM. 2020. Model-  
412 based Prediction of Critical Illness in Hospitalized Patients with COVID-19. *Radiology*  
413 **298**:E46–E54. doi:10.1148/radiol.2020202723
- 414 Sperrin M, Grant SW, Peek N. 2020. Prediction models for diagnosis and prognosis in Covid-19. *BMJ*  
415 **369**:m1464. doi:10.1136/bmj.m1464
- 416 Vezzoli M. 2011. Exploring the facets of overall job satisfaction through a novel ensemble learning.  
417 *Electron J Appl Stat Anal* **4**:23–38–38. doi:10.1285/i20705948v4n1p23
- 418 Vezzoli M, Ravaggi A, Zanotti L, Miscioscia RA, Bignotti E, Ragnoli M, Gambino A, Ruggeri G, Calza  
419 S, Sartori E, Odicino F. 2017. RERT: A Novel Regression Tree Approach to Predict Extruterine  
420 Disease in Endometrial Carcinoma Patients. *Sci Rep* **7**:10528. doi:10.1038/s41598-017-11104-4
- 421 Webb BJ, Peltan ID, Jensen P, Hoda D, Hunter B, Silver A, Starr N, Buckel W, Grisel N, Hummel E,  
422 Snow G, Morris D, Stenehjem E, Srivastava R, Brown SM. 2020. Clinical criteria for COVID-  
423 19-associated hyperinflammatory syndrome: a cohort study. *Lancet Rheumatol* **2**:e754–e763.  
424 doi:10.1016/S2665-9913(20)30343-X
- 425 Wynants L, Calster BV, Collins GS, Riley RD, Heinze G, Schuit E, Bonten MMJ, Dahly DL, Damen  
426 JA, Debray TPA, Jong VMT de, Vos MD, Dhiman P, Haller MC, Harhay MO, Henckaerts L,  
427 Heus P, Kammer M, Kreuzberger N, Lohmann A, Luijken K, Ma J, Martin GP, McLernon DJ,  
428 Navarro CLA, Reitsma JB, Sergeant JC, Shi C, Skoetz N, Smits LJM, Snell KIE, Sperrin M,  
429 Spijker R, Steyerberg EW, Takada T, Tzoulaki I, Kuijk SMJ van, Bussel BCT van, Horst ICC  
430 van der, Royen FS van, Verbakel JY, Wallisch C, Wilkinson J, Wolff R, Hooft L, Moons KGM,  
431 Smeden M van. 2020. Prediction models for diagnosis and prognosis of covid-19: systematic  
432 review and critical appraisal. *BMJ* **369**:m1328. doi:10.1136/bmj.m1328
- 433 Yavuz BG, Colak S, Guven R, Altundag İ, Seyhan AU, Inanc RG. 2021. Clinical Features of the 60  
434 Years and Older Patients Infected with 2019 Novel Coronavirus: Can We Predict Mortality  
435 Earlier? *Gerontology* 1–8. doi:10.1159/000514481
- 436

## Tables

**Table 1:** Descriptive statistics on all variables in the dataset stratified respect Alive-Dead. Comparison between first (March-April) and second (May-December) wave.

Variables	First wave: March-April (MA) 2020		p-value	Second wave: May-December (MD) 2020		p value
	Alive (N=1683)	Dead (N=423)		Alive (N=594)	Dead (N=82)	
<b>Age</b>			<b>&lt; 0.001*</b>			<b>&lt; 0.001*</b>
Mean (SD)	64.55 (14.27)	76.21 (9.12)		65.30 (15.20)	76.72 (10.79)	
Median	65.00	77.00		67.00	80.00	
(Q1, Q3)	(55.00, 75.00)	(72.00, 82.00)		(55.00, 77.00)	(72.25, 84.75)	
Range	19.00 - 97.00	44.00 - 98.00		18.00 - 97.00	44.00 - 98.00	
<b>Sex</b>			<b>0.036**</b>			<b>0.131**</b>
F	613 (36.4%)	131 (31.0%)		240 (40.4%)	26 (31.7%)	
M	1070 (63.6%)	292 (69.0%)		354 (59.6%)	56 (68.3%)	
<b>Days in hospital</b>			<b>&lt; 0.001*</b>			<b>0.008*</b>
N-Miss	1	0		95	0	
Mean (SD)	14.15 (11.66)	11.33 (10.98)		14.95 (11.67)	17.77 (10.75)	
Median	11.00	8.00		12.00	17.50	
(Q1, Q3)	(7.00, 18.00)	(4.00, 15.00)		(7.00, 20.00)	(9.00, 25.00)	
Range	0.00 - 140.00	0.00 - 88.00		0.00 - 79.00	2.00 - 46.00	
<b>Score</b>			<b>&lt; 0.001*</b>			<b>&lt; 0.001*</b>
Mean (SD)	6.92 (4.40)	8.77 (4.39)		5.65 (4.48)	8.23 (4.63)	
Median	7.00	9.00		5.00	9.00	
(Q1, Q3)	(3.00, 10.00)	(6.00, 12.00)		(2.00, 9.00)	(5.25, 11.00)	
Range	0.00 - 18.00	0.00 - 18.00		0.00 - 18.00	0.00 - 17.00	
<b>D-dimer</b>			<b>&lt; 0.001*</b>			<b>&lt; 0.001*</b>
N-Miss	406	113		128	16	
Mean (SD)	1155.03 (2218.51)	3124.25 (8070.21)		1538.17 (3123.38)	4712.44 (8897.82)	
Median	443.00	944.50		739.50	1112.00	
(Q1, Q3)	(262.00, 985.00)	(476.50, 2970.75)		(427.50, 1341.25)	(725.50, 3619.25)	
Range	200.00 - 47228.00	200.00 - 60342.00		190.00 - 33501.00	190.00 - 35000.00	
<b>Fibrinogen</b>			<b>0.951*</b>			<b>0.778*</b>

Variables	First wave: March-April (MA) 2020		p-value	Second wave: May-December (MD) 2020		
	Alive (N=1683)	Dead (N=423)		Alive (N=594)	Dead (N=82)	p value
N-Miss	339	117		54	8	
Mean (SD)	530.53 (194.13)	530.55 (213.69)		523.94 (169.43)	519.77 (213.05)	
Median	520.00	515.00		512.00	510.00	
(Q1, Q3)	(381.00, 650.00)	(381.00, 654.00)		(405.00, 612.00)	(330.50, 649.00)	
Range	119.00 - 1339.00	68.00 - 1333.00		147.00 - 1371.00	153.00 - 1287.00	
<b>LDH</b>			<b>&lt; 0.001*</b>			<b>&lt; 0.001*</b>
N-Miss	188	92		61	7	
Mean (SD)	321.25 (227.50)	433.71 (205.10)		308.30 (196.23)	443.49 (707.95)	
Median	283.00	406.00		273.00	332.00	
(Q1, Q3)	(222.00, 373.00)	(269.50, 545.50)		(218.00, 354.00)	(257.00, 442.50)	
Range	90.00 - 6689.00	123.00 - 1365.00		108.00 - 2565.00	122.00 - 6310.00	
<b>Neutrophils</b>			<b>&lt; 0.001*</b>			<b>&lt; 0.001*</b>
N-Miss	23	19		4	1	
Mean (SD)	5.67 (3.61)	7.17 (4.39)		5.80 (3.97)	7.21 (4.13)	
Median	4.83	6.20		4.78	6.72	
(Q1, Q3)	(3.29, 7.03)	(4.12, 9.02)		(3.42, 7.11)	(4.00, 9.77)	
Range	0.00 - 53.99	0.17 - 30.45		0.10 - 47.03	0.19 - 23.02	
<b>Lymphocytes</b>			<b>&lt; 0.001*</b>			<b>&lt; 0.001*</b>
N-Miss	23	19		4	1	
Mean (SD)	1.43 (5.48)	1.19 (4.29)		1.22 (0.81)	1.38 (4.63)	
Median	1.04	0.81		1.06	0.74	
(Q1, Q3)	(0.75, 1.42)	(0.55, 1.18)		(0.72, 1.52)	(0.47, 1.06)	
Range	0.10 - 177.63	0.04 - 85.51		0.08 - 10.28	0.08 - 42.20	
<b>Neutrophils on Lymphocytes</b>			<b>&lt; 0.001*</b>			<b>&lt; 0.001*</b>
N-Miss	23	19		4	1	
Mean (SD)	6.18 (5.87)	10.72 (11.71)		7.19 (9.92)	12.84 (13.09)	
Median	4.52	7.13		4.32	8.50	
(Q1, Q3)	(2.84, 7.50)	(4.47, 13.06)		(2.63, 8.40)	(4.05, 15.19)	
Range	0.00 - 101.90	0.01 - 129.67		0.12 - 143.25	0.11 - 70.56	
<b>Neutrophils %</b>			<b>&lt; 0.001*</b>			<b>&lt; 0.001*</b>
N-Miss	22	19		4	1	
Mean (SD)	0.73 (0.13)	0.80 (0.12)		0.73 (0.13)	0.79 (0.16)	
Median	0.74	0.82		0.73	0.83	

Variables	First wave: March-April (MA) 2020		p-value	Second wave: May-December (MD) 2020		p value
	Alive (N=1683)	Dead (N=423)		Alive (N=594)	Dead (N=82)	
(Q1, Q3)	(0.66, 0.82)	(0.75, 0.88)		(0.64, 0.83)	(0.69, 0.89)	
Range	0.00 - 0.97	0.01 - 0.97		0.10 - 0.99	0.10 - 0.96	
<b>Lymphocytes</b>			<b>&lt; 0.001*</b>			<b>&lt; 0.001*</b>
%						
N-Miss	22	19		4	1	
Mean (SD)	0.18 (0.11)	0.13 (0.09)		0.18 (0.11)	0.13 (0.13)	
Median	0.16	0.11		0.17	0.10	
(Q1, Q3)	(0.11, 0.23)	(0.07, 0.17)		(0.10, 0.25)	(0.06, 0.18)	
Range	0.01 - 0.97	0.01 - 0.99		0.01 - 0.88	0.01 - 0.88	
<b>PCR</b>			<b>&lt; 0.001*</b>			<b>0.004*</b>
N-Miss	47	12		21	0	
Mean (SD)	77.25 (75.76)	117.68 (95.97)		64.28 (73.38)	98.59 (102.49)	
Median	55.65	99.20		39.10	74.80	
(Q1, Q3)	(17.30, 111.60)	(42.80, 170.45)		(12.30, 91.10)	(20.12, 140.73)	
Range	0.30 - 479.00	0.70 - 471.10		0.30 - 483.20	0.30 - 593.80	
<b>WBC</b>			<b>&lt; 0.001*</b>			<b>0.011*</b>
N-Miss	21	19		4	1	
Mean (SD)	7.73 (7.13)	9.13 (7.46)		7.65 (4.17)	9.23 (6.25)	
Median	6.62	7.62		6.67	8.34	
(Q1, Q3)	(4.87, 9.11)	(5.60, 10.74)		(5.02, 8.90)	(5.55, 12.04)	
Range	0.72 - 191.02	0.32 - 92.23		0.97 - 48.19	0.97 - 47.79	
<b>Basophils</b>			0.073*			0.419*
N-Miss	23	19		4	1	
Mean (SD)	0.02 (0.02)	0.02 (0.02)		0.02 (0.04)	0.02 (0.02)	
Median	0.01	0.01		0.02	0.01	
(Q1, Q3)	(0.01, 0.02)	(0.01, 0.02)		(0.01, 0.03)	(0.01, 0.03)	
Range	0.00 - 0.31	0.00 - 0.15		0.00 - 0.84	0.00 - 0.11	
<b>Basophils %</b>			<b>&lt; 0.001*</b>			<b>0.024*</b>
N-Miss	22	19		4	1	
Mean (SD)	0.00 (0.00)	0.00 (0.00)		0.00 (0.00)	0.00 (0.00)	
Median	0.00	0.00		0.00	0.00	
(Q1, Q3)	(0.00, 0.00)	(0.00, 0.00)		(0.00, 0.00)	(0.00, 0.00)	
Range	0.00 - 0.02	0.00 - 0.06		0.00 - 0.05	0.00 - 0.01	
<b>Eosinophils</b>			<b>&lt; 0.001*</b>			<b>0.015*</b>

Variables	First wave: March-April (MA) 2020			Second wave: May-December (MD) 2020		
	Alive (N=1683)	Dead (N=423)	p-value	Alive (N=594)	Dead (N=82)	p value
N-Miss	23	19		4	1	
Mean (SD)	0.06 (0.12)	0.04 (0.10)		0.06 (0.14)	0.05 (0.13)	
Median (Q1, Q3)	0.01 (0.00, 0.07)	0.00 (0.00, 0.02)		0.01 (0.00, 0.06)	0.00 (0.00, 0.03)	
Range	0.00 - 2.19	0.00 - 0.79		0.00 - 1.95	0.00 - 0.97	
<b>Eosinophils %</b>			<b>&lt; 0.001*</b>			<b>0.013*</b>
N-Miss	22	19		4	1	
Mean (SD)	0.01 (0.02)	0.00 (0.01)		0.01 (0.02)	0.01 (0.01)	
Median (Q1, Q3)	0.00 (0.00, 0.01)	0.00 (0.00, 0.00)		0.00 (0.00, 0.01)	0.00 (0.00, 0.00)	
Range	0.00 - 0.27	0.00 - 0.12		0.00 - 0.25	0.00 - 0.07	
<b>Monocytes</b>			<b>&lt; 0.001*</b>			<b>0.683*</b>
N-Miss	23	19		4	1	
Mean (SD)	0.56 (0.68)	0.69 (3.32)		0.55 (0.32)	0.58 (0.41)	
Median (Q1, Q3)	0.47 (0.32, 0.68)	0.41 (0.25, 0.63)		0.49 (0.33, 0.68)	0.48 (0.27, 0.77)	
Range	0.01 - 23.31	0.02 - 66.34		0.02 - 2.45	0.07 - 2.01	
<b>Monocytes %</b>			<b>&lt; 0.001*</b>			<b>0.034*</b>
N-Miss	22	19		4	1	
Mean (SD)	0.08 (0.04)	0.07 (0.05)		0.08 (0.04)	0.07 (0.05)	
Median (Q1, Q3)	0.07 (0.05, 0.10)	0.06 (0.04, 0.08)		0.07 (0.05, 0.10)	0.06 (0.04, 0.09)	
Range	0.00 - 0.70	0.01 - 0.72		0.01 - 0.31	0.01 - 0.27	p value
<b>Ferritin F</b>	<b>613 patients (82.39%)</b>	<b>131 patients (17.61%)</b>	<b>&lt; 0.001*</b>	<b>240 patients (90.23%)</b>	<b>26 patients (9.77%)</b>	<b>0.372*</b>
N-Miss	158	34		43	5	
Mean (SD)	674.53 (817.61)	1237.07 (2308.64)		564.63 (526.39)	2006.00 (4680.23)	
Median (Q1, Q3)	459.00 (212.00, 820.50)	700.00 (353.00, 1347.00)		433.00 (216.00, 750.00)	510.00 (269.00, 722.00)	
Range	4.00 - 7687.00	19.00 - 20572.00		11.00 - 3397.00	81.00 - 20941.00	
<b>Ferritin M</b>	<b>1070 patients (78.56%)</b>	<b>292 patients (21.44%)</b>	<b>&lt; 0.001*</b>	<b>354 patients (90.23%)</b>	<b>56 patients (9.77%)</b>	<b>0.007*</b>
N-Miss	257	96		50	5	

Variables	First wave: March-April (MA) 2020			Second wave: May-December (MD) 2020		
	Alive (N=1683)	Dead (N=423)	p-value	Alive (N=594)	Dead (N=82)	p value
Mean (SD)	1353.00 (1359.86)	1825.25 (1945.47)		1181.95 (3295.92)	1372.04 (1258.14)	
Median	939.00	1262.50		737.50	1159.00	
(Q1, Q3)	(461.00, 1705.00)	(572.25, 2323.25)		(405.25, 1283.00)	(598.00, 1500.00)	
Range	23.00 - 11513.00	55.00 - 13289.00		25.00 - 56039.00	112.00 - 7058.00	

In bold and italics p-values<0.05

\* Wilcoxon rank-sum test t

\*\* Fisher's exact test


**Table 2:** Performance metrics of methods: Random Forest, Gradient Boosting Machine (GBM) and Logistic Regression

Metrics	Random Forest			GBM			LOGISTIC REGRESSION		
	Training March- April (MA)	Validating March- April (MA)	Testing May-Dec (MD)	Training March- April (MA)	Validating March- April (MA)	Testing May-Dec (MD)	Training March- April (MA)	Validating March- April (MA)	Testing May-Dec (MD)
<b>AUC (DeLong) (95% CI)</b>	0.97 (0.97-0.98)	0.83 (0.80-0.87)	0.78 (0.73-0.84)	0.88 (0.86-0.89)	0.84 (0.80-0.88)	0.78 (0.73-0.83)	0.84 (0.82-0.86)	0.83 (0.79-0.87)	0.52 (0.44-0.60)
<b>Sensitivity (95% CI)</b>	0.93 (0.91-0.97)	0.82 (0.72-0.92)	0.73 (0.54-1.00)	0.85 (0.80-0.88)	0.80 (0.66-0.90)	0.77 (0.65-0.94)	0.80 (0.77-0.84)	0.84 (0.76-0.91)	0.87 (0.18-1.00)
<b>Specificity (95% CI)</b>	0.92 (0.88-0.94)	0.75 (0.63-0.83)	0.73 (0.41-0.89)	0.77 (0.73-0.81)	0.75 (0.65-0.87)	0.71 (0.50-0.79)	0.74 (0.70 -0.77)	0.73 (0.65-0.79)	0.26 (0.11-0.94)

Comparison between the performances of three methods: Random Forest, GBM and Logistic Regression model applied on the rebalanced dataset obtained with SMOTE methodology. Logistic Regression predictions are computed using the 10-fold cross-validation in order to be comparable with Random Forest and GBM predictions (which use out-of-bag and 10-fold cross-validation, respectively).

## Figures


**Figure 1:** Flow-chart of the data used in the empirical analyses



The BS-EWM was trained with a Random Forest on 70% of first wave patients (rebalanced with the SMOTE procedure) and (i) validated on remaining 30% of first wave patients (ii) tested on 676 second wave patients. In detail, 2106 patients were randomly in training and validating, maintaining the same death prevalence of the first wave.




**Figure 2: Relative Variable importance Measure (rel VIM) and PDP**



**PANEL A:** Relative Variable importance Measure (rel VIM) extracted from the Random Forest considering “Age” (A1) or excluding “Age” (A2).

**Panel B:** Partial Dependence Plot (PDP) in correspondence of variables with  $VIM > 60$  (cut-off identified by the red dashed line) extracted from Random Forest without “Age” (A2) and p-value in Table 1  $< 0.05$ . PDPs are displayed from the most to the less important variable.

**Figure 3:** ROC curves of Random Forest, GBM and Logistic Regression



ROC curves of three methods: (i) Random Forest, (ii) GBM and (iii) Logistic Regression. Each graph reports the ROC curve computed in Training (blue line, 70% of March-April's patients) Validating (dashed red line, 30% of March-April's patients), and Testing (dashed green lined, May-December patients).

## Supplementary Tables

**Table S.1:** Descriptive statistics on all variables of the entire sample

<b>Variables</b>	<b>Overall (N=2782)</b>
<b>Age</b>	
Mean (SD)	66.84 (14.44)
Median (Q1, Q3)	69.00 (57.00, 78.00)
Range	18.00 - 98.00
<b>Sex</b>	
F	1010 (36.3%)
M	1772 (63.7%)
<b>Days in hospital</b>	
N-Miss	96
Mean (SD)	13.96 (11.60)
Median (Q1, Q3)	11.00 (6.00, 18.00)
Range	0.00 - 140.00
<b>Score</b>	
Mean (SD)	6.97 (4.52)
Median (Q1, Q3)	7.00 (3.00, 10.00)
Range	0.00 - 18.00
<b>D-dimer</b>	
N-Miss	663
Mean (SD)	1638.18 (4218.89)
Median (Q1, Q3)	578.00 (315.50, 1289.50)
Range	190.00 - 60342.00
<b>Fibrinogen</b>	
N-Miss	518
Mean (SD)	528.61 (191.92)
Median (Q1, Q3)	515.00 (391.00, 637.00)
Range	68.00 - 1371.00
<b>LDH</b>	
N-Miss	348
Mean (SD)	337.48 (251.21)
Median (Q1, Q3)	291.50 (226.00, 395.00)
Range	90.00 - 6689.00
<b>Neutrophils</b>	
N-Miss	47
Mean (SD)	5.96 (3.87)
Median (Q1, Q3)	5.03 (3.43, 7.48)
Range	0.00 - 53.99
<b>Lymphocytes</b>	
N-Miss	47
Mean (SD)	1.35 (4.66)
Median (Q1, Q3)	1.00 (0.69, 1.40)
Range	0.04 - 177.63
<b>Neutrophils on Lymphocytes</b>	
N-Miss	47
Mean (SD)	7.27 (8.41)
Median (Q1, Q3)	4.89 (2.96, 8.69)
Range	0.00 - 143.25
<b>Neutrophils %</b>	
N-Miss	46
Mean (SD)	0.74 (0.13)
Median (Q1, Q3)	0.76 (0.67, 0.84)
Range	0.00 - 0.99
<b>Lymphocytes %</b>	
N-Miss	46
Mean (SD)	0.17 (0.11)
Median (Q1, Q3)	0.16 (0.10, 0.23)
Range	0.01 - 0.99

<b>Variables</b>	<b>Overall (N=2782)</b>
<b>PCR</b>	
N-Miss	80
Mean (SD)	81.30 (81.30)
Median (Q1, Q3)	56.70 (18.20, 117.55)
Range	0.30 - 593.80
<b>WBC</b>	
N-Miss	45
Mean (SD)	7.97 (6.65)
Median (Q1, Q3)	6.82 (5.00, 9.40)
Range	0.32 - 191.02
<b>Basophils</b>	
N-Miss	47
Mean (SD)	0.02 (0.03)
Median (Q1, Q3)	0.01 (0.01, 0.03)
Range	0.00 - 0.84
<b>Basophils %</b>	
N-Miss	46
Mean (SD)	0.00 (0.00)
Median (Q1, Q3)	0.00 (0.00, 0.00)
Range	0.00 - 0.06
<b>Eosinophils</b>	
N-Miss	47
Mean (SD)	0.05 (0.12)
Median (Q1, Q3)	0.01 (0.00, 0.06)
Range	0.00 - 2.19
<b>Eosinophils %</b>	
N-Miss	46
Mean (SD)	0.01 (0.02)
Median (Q1, Q3)	0.00 (0.00, 0.01)
Range	0.00 - 0.27
<b>Monocytes</b>	
N-Miss	47
Mean (SD)	0.58 (1.39)
Median (Q1, Q3)	0.47 (0.31, 0.68)
Range	0.01 - 66.34
<b>Monocytes %</b>	
N-Miss	46
Mean (SD)	0.08 (0.04)
Median (Q1, Q3)	0.07 (0.05, 0.10)
Range	0.00 - 0.72

**Table S.2:** Descriptive statistics on all variables in the dataset stratified respect first (March-April 2020) and second (May-December 2020) wave. Comparison between Alive and Dead.

Variables	Alive		p-value	Dead		p value
	March-April (MA) (N=1683)	May-December (MD) (N=594)		March-April (MA) (N=423)	May-December (MD) (N=82)	
<b>Age</b>			0.1503*			0.2041*
Mean (SD)	64.55 (14.27)	65.30 (15.20)		76.21 (9.12)	76.72 (10.79)	
Median	65.00	67.00		77.00	80.00	
(Q1, Q3)	(55.00, 75.00)	(55.00, 77.00)		(72.00, 82.00)	(72.25, 84.75)	
Range	19.00 - 97.00	18.00 - 97.00		44.00 - 98.00	44.00 - 98.00	
<b>Sex</b>			0.0936**			0.8968**
F	613 (36.4%)	240 (40.4%)		131 (31.0%)	26 (31.7%)	
M	1070 (63.6%)	354 (59.6%)		292 (69.0%)	56 (68.3%)	
<b>Days in hospital</b>			0.2122*			< 0.001*
N-Miss	1	95		0	0	
Mean (SD)	14.15 (11.66)	14.95 (11.67)		11.33 (10.98)	17.77 (10.75)	
Median	11.00	12.00		8.00	17.50	
(Q1, Q3)	(7.00, 18.00)	(7.00, 20.00)		(4.00, 15.00)	(9.00, 25.00)	
Range	0.00 - 140.00	0.00 - 79.00		0.00 - 88.00	2.00 - 46.00	
<b>Score</b>			< 0.001*			0.3965*
Mean (SD)	6.92 (4.40)	5.65 (4.48)		8.77 (4.39)	8.23 (4.63)	
Median	7.00	5.00		9.00	9.00	
(Q1, Q3)	(3.00, 10.00)	(2.00, 9.00)		(6.00, 12.00)	(5.25, 11.00)	
Range	0.00 - 18.00	0.00 - 18.00		0.00 - 18.00	0.00 - 17.00	
<b>D-dimer</b>			< 0.001*			0.0452*
N-Miss	406	128		113	16	
Mean (SD)	1155.03 (2218.51)	1538.17 (3123.38)		3124.25 (8070.21)	4712.44 (8897.82)	
Median	443.00	739.50		944.50	1112.00	
(Q1, Q3)	(262.00, 985.00)	(427.50, 1341.25)		(476.50, 2970.75)	(725.50, 3619.25)	
Range	200.00 - 47228.00	190.00 - 33501.00		200.00 - 60342.00	190.00 - 35000.00	
<b>Fibrinogen</b>			0.7502*			0.6711*
N-Miss	339	54		117	8	
Mean (SD)	530.53 (194.13)	523.94 (169.43)		530.55 (213.69)	519.77 (213.05)	
Median	520.00	512.00		515.00	510.00	
(Q1, Q3)	(381.00, 650.00)	(405.00, 612.00)		(381.00, 654.00)	(330.50, 649.00)	
Range	119.00 - 1339.00	147.00 - 1371.00		68.00 - 1333.00	153.00 - 1287.00	
<b>LDH</b>			0.0298*			0.0094*
N-Miss	188	61		92	7	
Mean (SD)	321.25 (227.50)	308.30 (196.23)		433.71 (205.10)	443.49 (707.95)	
Median	283.00	273.00		406.00	332.00	
(Q1, Q3)	(222.00, 373.00)	(218.00, 354.00)		(269.50, 545.50)	(257.00, 442.50)	
Range	90.00 - 6689.00	108.00 - 2565.00		123.00 - 1365.00	122.00 - 6310.00	
<b>Neutrophils</b>			0.8529*			0.6350*
N-Miss	23	4		19	1	
Mean (SD)	5.67 (3.61)	5.80 (3.97)		7.17 (4.39)	7.21 (4.13)	
Median	4.83	4.78		6.20	6.72	
(Q1, Q3)	(3.29, 7.03)	(3.42, 7.11)		(4.12, 9.02)	(4.00, 9.77)	
Range	0.00 - 53.99	0.10 - 47.03		0.17 - 30.45	0.19 - 23.02	

Variables	Alive		p-value	Dead		p value
	March-April (MA) (N=1683)	May-December (MD) (N=594)		March-April (MA) (N=423)	May-December (MD) (N=82)	
<b>Lymphocytes</b>			0.6287*			0.2115*
N-Miss	23	4		19	1	
Mean (SD)	1.43 (5.48)	1.22 (0.81)		1.19 (4.29)	1.38 (4.63)	
Median	1.04	1.06		0.81	0.74	
(Q1, Q3)	(0.75, 1.42)	(0.72, 1.52)		(0.55, 1.18)	(0.47, 1.06)	
Range	0.10 - 177.63	0.08 - 10.28		0.04 - 85.51	0.08 - 42.20	
<b>Neutrophils on Lymphocytes</b>			0.8639*			0.3122*
N-Miss	23	4		19	1	
Mean (SD)	6.18 (5.87)	7.19 (9.92)		10.72 (11.71)	12.84 (13.09)	
Median	4.52	4.32		7.13	8.50	
(Q1, Q3)	(2.84, 7.50)	(2.63, 8.40)		(4.47, 13.06)	(4.05, 15.19)	
Range	0.00 - 101.90	0.12 - 143.25		0.01 - 129.67	0.11 - 70.56	
<b>Neutrophils %</b>			0.6134*			0.6882*
N-Miss	22	4		19	1	
Mean (SD)	0.73 (0.13)	0.73 (0.13)		0.80 (0.12)	0.79 (0.16)	
Median	0.74	0.73		0.82	0.83	
(Q1, Q3)	(0.66, 0.82)	(0.64, 0.83)		(0.75, 0.88)	(0.69, 0.89)	
Range	0.00 - 0.97	0.10 - 0.99		0.01 - 0.97	0.10 - 0.96	
<b>Lymphocytes %</b>			0.933*			0.2924*
N-Miss	22	4		19	1	
Mean (SD)	0.18 (0.11)	0.18 (0.11)		0.13 (0.09)	0.13 (0.13)	
Median	0.16	0.17		0.11	0.10	
(Q1, Q3)	(0.11, 0.23)	(0.10, 0.25)		(0.07, 0.17)	(0.06, 0.18)	
Range	0.01 - 0.97	0.01 - 0.88		0.01 - 0.99	0.01 - 0.88	
<b>PCR</b>			< 0.001*			0.0235*
N-Miss	47	21		12	0	
Mean (SD)	77.25 (75.76)	64.28 (73.38)		117.68 (95.97)	98.59 (102.49)	
Median	55.65	39.10		99.20	74.80	
(Q1, Q3)	(17.30, 111.60)	(12.30, 91.10)		(42.80, 170.45)	(20.12, 140.73)	
Range	0.30 - 479.00	0.30 - 483.20		0.70 - 471.10	0.30 - 593.80	
<b>WBC</b>			0.4686*			0.6138*
N-Miss	21	4		19	1	
Mean (SD)	7.73 (7.13)	7.65 (4.17)		9.13 (7.46)	9.23 (6.25)	
Median	6.62	6.67		7.62	8.34	
(Q1, Q3)	(4.87, 9.11)	(5.02, 8.90)		(5.60, 10.74)	(5.55, 12.04)	
Range	0.72 - 191.02	0.97 - 48.19		0.32 - 92.23	0.97 - 47.79	
<b>Basophils</b>			0.0013*			0.2253*
N-Miss	23	4		19	1	
Mean (SD)	0.02 (0.02)	0.02 (0.04)		0.02 (0.02)	0.02 (0.02)	
Median	0.01	0.02		0.01	0.01	
(Q1, Q3)	(0.01, 0.02)	(0.01, 0.03)		(0.01, 0.02)	(0.01, 0.03)	
Range	0.00 - 0.31	0.00 - 0.84		0.00 - 0.15	0.00 - 0.11	
<b>Basophils %</b>			0.0012*			0.1017*
N-Miss	22	4		19	1	
Mean (SD)	0.00 (0.00)	0.00 (0.00)		0.00 (0.00)	0.00 (0.00)	
Median	0.00	0.00		0.00	0.00	
(Q1, Q3)	(0.00, 0.00)	(0.00, 0.00)		(0.00, 0.00)	(0.00, 0.00)	
Range	0.00 - 0.02	0.00 - 0.05		0.00 - 0.06	0.00 - 0.01	
<b>Eosinophils</b>			0.4863*			0.9056*
N-Miss	23	4		19	1	

Variables	Alive		p-value	Dead		p value
	March-April (MA) (N=1683)	May-December (MD) (N=594)		March-April (MA) (N=423)	May-December (MD) (N=82)	
Mean (SD)	0.06 (0.12)	0.06 (0.14)		0.04 (0.10)	0.05 (0.13)	
Median	0.01	0.01		0.00	0.00	
(Q1, Q3)	(0.00, 0.07)	(0.00, 0.06)		(0.00, 0.02)	(0.00, 0.03)	
Range	0.00 - 2.19	0.00 - 1.95		0.00 - 0.79	0.00 - 0.97	
<b>Eosinophils %</b>			0.4902*			0.9885*
N-Miss	22	4		19	1	
Mean (SD)	0.01 (0.02)	0.01 (0.02)		0.00 (0.01)	0.01 (0.01)	
Median	0.00	0.00		0.00	0.00	
(Q1, Q3)	(0.00, 0.01)	(0.00, 0.01)		(0.00, 0.00)	(0.00, 0.00)	
Range	0.00 - 0.27	0.00 - 0.25		0.00 - 0.12	0.00 - 0.07	
<b>Monocytes</b>			0.253*			0.1643*
N-Miss	23	4		19	1	
Mean (SD)	0.56 (0.68)	0.55 (0.32)		0.69 (3.32)	0.58 (0.41)	
Median	0.47	0.49		0.41	0.48	
(Q1, Q3)	(0.32, 0.68)	(0.33, 0.68)		(0.25, 0.63)	(0.27, 0.77)	
Range	0.01 - 23.31	0.02 - 2.45		0.02 - 66.34	0.07 - 2.01	
<b>Monocytes %</b>			0.6814*			0.2654*
N-Miss	22	4		19	1	
Mean (SD)	0.08 (0.04)	0.08 (0.04)		0.07 (0.05)	0.07 (0.05)	
Median	0.07 (0.05, 0.10)	0.07 (0.05, 0.10)		0.06 (0.04, 0.08)	0.06 (0.04, 0.09)	
Range	0.00 - 0.70	0.01 - 0.31		0.01 - 0.72	0.01 - 0.27	p value
<b>Ferritin F</b>	<b>613 patients (82.39%)</b>	<b>240 patients (90.23%)</b>	0.4706*	<b>131 patients (17.61%)</b>	<b>26 patients (9.77%)</b>	0.3985*
N-Miss	158	43		34	5	
Mean (SD)	674.53 (817.61)	564.63 (526.39)		1237.07 (2308.64)	2006.00 (4680.23)	
Median	459.00	433.00		700.00	510.00	
(Q1, Q3)	(212.00, 820.50)	(216.00, 750.00)		(353.00, 1347.00)	(269.00, 722.00)	
Range	4.00 - 7687.00	11.00 - 3397.00		19.00 - 20572.00	81.00 - 20941.00	
<b>Ferritin M</b>	<b>1070 patients (78.56%)</b>	<b>354 patients (90.23%)</b>	<b>&lt; 0.001*</b>	<b>292 patients (21.44%)</b>	<b>56 patients (9.77%)</b>	0.1555*
N-Miss	257	50		96	5	
Mean (SD)	1353.00 (1359.86)	1181.95 (3295.92)		1825.25 (1945.47)	1372.04 (1258.14)	
Median	939.00	737.50		1262.50	1159.00	
(Q1, Q3)	(461.00, 1705.00)	(405.25, 1283.00)		(572.25, 2323.25)	(598.00, 1500.00)	
Range	23.00 - 11513.00	25.00 - 56039.00		55.00 - 13289.00	112.00 - 7058.00	

In bold and italics p-values<0.05

\* Wilcoxon rank-sum test t

\*\* Fisher's exact test




**Table S.3:** Performance metrics of the Random Forest (RF) using or not a rebalanced dataset with the SMOTE methodology

Metrics	RF on a dataset rebalanced with the SMOTE methodology		RF on the original dataset	
	Training March-April (MA) (95% CI)	Validating March-April (MA) (95% CI)	Training March-April (MA) (95% CI)	Validating March-April (MA) (95% CI)
<b>AUC (DeLong)</b>	0.97-0.98	0.80-0.87	0.82-0.86	0.81-0.88
<b>Sensitivity</b>	0.93 (0.91-0.97)	0.82 (0.72-0.92)	0.81 (0.76-0.85)	0.79 (0.66-0.95)
<b>Specificity</b>	0.92 (0.88-0.94)	0.75 (0.63-0.83)	0.76 (0.73-0.79)	0.76 (0.57-0.86)

In this table we compare the performance of two RFs applied on (i) a dataset rebalanced with the SMOTE methodology (ii) the original dataset. This analysis suggests the use of SMOTE methodology before applying RF since the performance in Training and Validating groups (especially in terms of sensitivity) are better respect those obtained from the RF grown on the original dataset.

**Figure S.1:** Correlation plot between the 17 analytes and Brescia chest-xray



The relationships between 17 analytes and Brescia chest-xray score are inspected with the Spearman correlation coefficients,  $\rho_s$  which are represented in this correlation plot by means of blue and red circles (positive and negative correlation, respectively). The diameter of the circle is proportional to the magnitude of  $\rho_s$  and black crosses on them identify correlation not significantly different from zero ( $p$ -values  $> 0.05$ ). The correlation matrix is reordered according to the hierarchical cluster analysis on the quantitative variables.